



Biocure Technology

December 18, 2017

FOR IMMEDIATE RELEASE

BioCure Enters Into Land Purchase Agreement

Vancouver, British Columbia – December 18, 2017 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) is pleased to announce that on December 12, 2017 the company’s subsidiary, Biocurepharm Corporation (“BP Korea”) entered into a land purchase agreement (the “Agreement”) with Korea Land & Housing Corporation (“KLHC”), a state-run land and housing development company in Korea, for the acquisition of a 6,060m² industrial usage parcel. The acquisition cost for the land is KRW2,813,950,000 (the “Purchase Price”) (approximately C\$3,317,647.05 utilizing an exchange rate of C\$0.001179/1KRW, Dec. 12, 2017, Bank of Canada).

On the execution of the Agreement, BP Korea paid 10% of the Purchase Price, being KRW 281,395,500 (approximately CDN\$331,765). The balance of the Purchase Price is payable in six substantially equal installments of approximately KRW 422,000,000 (approximately CDN\$663,350) every six months commencing on Jun. 12, 2018 until Dec. ~~12~~²⁴, 2020.

The payment schedule, including applicable interest payments due, is as follows;

Payment schedule					
Classification	Due date	Installment Principal	Installment Interest	Amount to be paid	Balance outstanding
Down payment	2017-12-12	KW281,395,000	0	KW281,395,000	KW2,545,868,230
1 st payment	2018-06-12	KW422,555,000	0	KW422,555,000	KW2,123,313,230
2 nd payment	2018-12-12	KW422,000,000	0	KW422,000,000	KW1,701,313,230
3 rd payment	2019-06-12	KW422,000,000	0	KW422,000,000	KW1,279,313,230
4 th payment	2019-12-12	KW422,000,000	0	KW422,000,000	KW857,313,230
5 th payment	2020-06-12	KW422,000,000	KW5,908,000	KW427,908,000	KW429,405,230
Final payment	2020-12-12	KW422,000,000	KW7,405,230	KW429,405,230	0

The purpose of the land purchase is provide for manufacturing facilities of the Company's biosimilar products as well as CAR T-Cell products under the previously announced joint venture Pharos Vaccine Inc (see the Company's news release dated December 4, 2017). KLHC plans to complete land formation work by the end of 2019 with architecture design and construction for the manufacturing facilities following.

The land is a part of the International Science Business Belt (the "ISB Belt"), specially zoned by the Korean Ministry of Science and ICT (Information, Communication, Technology)(MSICT). MSICT receives and reviews all applications from companies who would like to acquire space in the ISB Belt approves those it considers qualified. Companies selected by MSICT are permitted to acquire the lands at a discount of approximately half the price of the similar lands in the vicinity.

BP Korea plans to apply for a loan from a Korean local bank to fund the Purchase Price remaining to be paid pursuant to the payment schedule. BP Korea anticipates it will be able to access policy funds which would allow the Company to pay interest only for the first three years and principal for the next five years. The Company anticipates it will need to raise additional funds to meet its ongoing business objectives, including the purchase of the land, in the second quarter of 2018.

Dr. Sang Mok Lee, a CEO & President of the Company stated, *"We are excited to have been qualified and selected to acquire the land from the International Science Business Belt designed by MSICT at the lowest cost possible. This acquisition will give us momentum to expedite the commercial production of the key products we are working on."*

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, Filgrastim and Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.

ON BEHALF OF THE BOARD OF DIRECTORS

/s/ *"Sang Mok Lee"*

CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604 609-7146

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement, the Company's ability to achieve sales, commercial or otherwise, from its products, and the expectations of the Company

regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements.

Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.